Skip to main
Thymosin Alpha-1 Review

Pancreatic infections, immune trials and a medicine’s particular job.

A thymosin alpha 1 reading list

Pancreatic infections and sepsis

The pancreatitis meta-analysis asks about infectious complications during severe pancreatic inflammation. ETASS and TESTS put the survival question to patients with sepsis. Their results make much more sense alongside each other than as isolated favourable percentages.

For other clinical uses, the list includes hepatitis trials, HIV immune recovery, vaccine response and cancer combinations. Some entries are primary trials, some reviews and one a Cochrane review protocol that summarises earlier hepatitis work. Their different roles matter when following a result back to its origin.

Origin and safety

The 1977 isolation paper supplies the molecular starting point. The human pharmacokinetic study concerns blood clearance, and the 2024 safety review gathers clinical tolerability experience. The safety review is my reminder that an efficacy debate can crowd the everyday adverse-event record out of the conversation.

All source entries follow below, including work discussed elsewhere on the site.

  1. You J, Zhuang L, Tang BZ, et al. Randomized controlled clinical trial on the treatment of Thymosin-a1 vs interferon-alpha in patients with hepatitis B. World J Gastroenterol. 2001;7(3):411-414. ↗
  2. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. ↗
  3. Liu F, Wang HM, Wang T, Zhang YM, Zhu X. The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis. 2016;16(1):488. ↗
  4. TESTS trial investigators. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025. ↗
  5. Serafino A, Pica F, et al. Thymosin alpha1 Activates Complement Receptor-Mediated Phagocytosis in Human Monocyte-Derived Macrophages. J Innate Immun. 2014;6(1):72-84. ↗
  6. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int. 2009;3(3):480-489. ↗
  7. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019;9:873. ↗
  8. Tao N, Xu X, Ying Y, et al. Thymosin alpha1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023;28(8):3539. ↗
  9. Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin alpha1 levels in patients with chronic inflammatory autoimmune diseases. Clin Exp Immunol. 2016;186(1):39-45. ↗
  10. Chen C, Wang J, Xun J, et al. Role of thymosin alpha1 in restoring immune response in immunological nonresponders living with HIV. BMC Infect Dis. 2024;24(1):117. ↗
  11. Benitez G, Shehadeh F, Mylona EK, et al. Effect of thymalfasin (Thymosin-alpha-1) on reversing lymphocytopenia among patients with COVID-19. Int Immunopharmacol. 2023;116:109831. ↗
  12. Gravenstein S, Duthie EH, Miller BA, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J Am Geriatr Soc. 1989;37(1):1-8. ↗
  13. Tian Y, Yao J, Ma Y, et al. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Front Immunol. 2025;16:1571456. ↗
  14. Simonova MA, Ivanov I, Shoshina NS, Komyakova AM, et al. Aging and Thymosin Alpha-1. Int J Mol Sci. 2025;26(23):11470. ↗
  15. Htet NH, Naing C, Vongpunsawad S, Win TT, Poovorawan Y. Thymosin-alpha-1 for people with chronic hepatitis B (Cochrane protocol referencing prior meta-analyses). Cochrane Database Syst Rev. 2022. ↗
  16. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725-729. ↗
  17. Garaci E, et al. Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers. J Pharm Pharmacol. 1999;51(2):185-191. ↗
  18. Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024. ↗
  19. Andreone P, Gramenzi A, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. J Viral Hepat. 1998;5(2):99-104. ↗
  20. Garaci E, Perno CF, et al. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Infect Dis. 2004;38(2):273-280. ↗